Cemiplimab: Mechanism, Uses, Risks, And What To Know

What is cemiplimab?

Cemiplimab (also called cemiplimab-rwlc; trade name Libtayo®) is a prescription medicine used primarily to treat adults with certain types of advanced skin cancers. It belongs to a class of drugs known as immune checkpoint inhibitors, specifically a monoclonal antibody that targets the programmed death-1 (PD-1) receptor. By blocking PD-1, cemiplimab unleashes the body’s T cells to attack and destroy cancer cells, offering a novel approach for patients who are not candidates for surgery or radiation.

Developed by Regeneron Pharmaceuticals and Sanofi, cemiplimab received breakthrough therapy designation from the US Food and Drug Administration (FDA) in September 2018 for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC). It was the first FDA-approved treatment specifically for this indication. The European Medicines Agency (EMA) also granted marketing authorization in 2019, with further expansions for basal cell carcinoma (BCC) and other cancers.

This immunotherapy has transformed the management of non-melanoma skin cancers, providing durable responses in patients with limited options. Clinical trials like EMPOWER-CSCC 1 demonstrated objective response rates of 44.9% to 50.8%, with many patients achieving long-term remission.

How does cemiplimab work?

Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to the PD-1 receptor on the surface of T cells. Under normal conditions, PD-1 interacts with its ligands, PD-L1 and PD-L2, which are expressed on antigen-presenting cells and tumour cells. This interaction inhibits T-cell activation, proliferation, cytokine production, and cytotoxicity, helping maintain immune tolerance and prevent autoimmunity.

Cancer cells exploit this pathway by upregulating PD-L1 on their surface, creating an immunosuppressive environment that allows tumour evasion. Cemiplimab blocks the PD-1/PD-L1 interaction, reinvigorating exhausted T cells to mount an effective anti-tumour response. This immune-mediated mechanism promotes T-cell infiltration into tumours, leading to cancer cell destruction.

Pharmacodynamically, cemiplimab enhances T-cell function without directly killing cancer cells, distinguishing it from traditional chemotherapies. Its high affinity for PD-1 ensures potent blockade, with pharmacokinetics showing a half-life of approximately 20 days, supporting every-3-week dosing.

How is cemiplimab used?

Cemiplimab is administered as an intravenous (IV) infusion over 30 minutes, every 3 weeks, at a dose of 350 mg. Treatment continues until disease progression, unacceptable toxicity, or up to 24 months.

• For CSCC: Indicated for locally advanced or metastatic CSCC in patients not eligible for curative surgery or radiation. Pooled phase II trial data show median progression-free survival of 18.4 months and 24-month overall survival of 73.3%.
• For BCC: Used in locally advanced or metastatic BCC after progression on or intolerance to hedgehog pathway inhibitors. Objective response rates are 31% (locally advanced) and 22% (metastatic).
• Other indications: Non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% (no EGFR/ALK/ROS1 aberrations), and cervical cancer.

Dilution and administration require healthcare professional oversight to prevent infusion reactions. Premedication is not routinely needed, but monitoring for hypersensitivity is essential.

Potential drug interactions

As a monoclonal antibody, cemiplimab has minimal pharmacokinetic interactions with small-molecule drugs, as it is not metabolized by cytochrome P450 enzymes. However, its immunomodulatory effects can interact with other therapies:

• Immunosuppressants: Corticosteroids or TNF blockers may reduce efficacy by dampening immune activation.
• Other checkpoint inhibitors: Combinations (e.g., with CTLA-4 inhibitors) are under study but increase toxicity risk.
• Vaccines: Live vaccines are contraindicated due to risk of disseminated infection.
• Chemotherapy/radiation: May be used sequentially, but concurrent use requires caution for additive immune-related adverse events (irAEs).

No dose adjustments are needed for renal/hepatic impairment, but monitor closely in patients on CYP substrates, as inflammation from irAEs can alter metabolism.

Adverse events and risks

Cemiplimab is generally well-tolerated, but immune activation can cause irAEs in up to 20-30% of patients. Common adverse events (≥10%) include fatigue, rash, diarrhoea, musculoskeletal pain, and pruritus. Serious risks include immune-mediated reactions affecting organs like skin, GI tract, liver, lungs, endocrine glands, and kidneys.

Fatal irAEs occur in <1%, but early recognition is critical. Baseline and periodic monitoring of thyroid, liver, and renal function is recommended. In trials, discontinuation due to toxicity was around 10%.

Long-term risks include chronic endocrinopathies and secondary malignancies from immune dysregulation, though rare.

Uses in specific populations

• Pregnancy: Category not assigned; animal studies show no direct harm, but potential fetal B-cell depletion. Use only if benefits outweigh risks; effective contraception advised during and 4 months post-treatment.
• Lactation: Unknown if excreted in milk; recommend withholding breastfeeding.
• Pediatrics: Safety/efficacy not established.
• Elderly: No age-related differences; used safely in patients >65 years.
• Renal/Hepatic impairment: No adjustments needed.
• Transplant/autoimmune patients: Limited data; heightened irAE risk and potential graft rejection. Real-world studies ongoing.

Multidisciplinary care involving dermatologists, oncologists, and endocrinologists optimizes outcomes.

Frequently Asked Questions

What is the success rate of cemiplimab for CSCC?

Objective response rates range from 44-53%, with durable responses up to 24 months in metastatic CSCC.

How long does cemiplimab treatment last?

Up to 24 months or until progression/toxicity.

Is cemiplimab a chemotherapy?

No, it’s an immunotherapy that boosts the immune system, not a cytotoxic drug.

Can cemiplimab cure skin cancer?

It induces complete responses in 10-20% of cases, but ‘cure’ varies by stage; many achieve long-term control.

What are the most common side effects?

Fatigue, skin rash, diarrhoea, and thyroid issues.

Clinical Efficacy Highlights

In pivotal trials:

• CSCC: 73.3% 24-month OS.
• BCC la/m: ORR 22-31%, CR 1.9-6%.

Ongoing research explores neoadjuvant use and combinations for broader applications.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb